SCYNEXIS Business Summary

SCYNEXIS INC (SCYX) is a biotechnology firm that generates revenue through a strategic licensing and royalty-based business model, primarily centered on its "fungerp" class of antifungal agents. The company’s financial structure was significantly reshaped by a 2023 global licensing agreement with GSK for its lead product, ibrexafungerp (BREXAFEMME), which provides SCYNEXIS with tiered royalties and milestone payments. In late 2025, the company resolved a clinical dispute with GSK, receiving approximately $24.8 million in total payments to terminate the Phase 3 MARIO study while clearing the path for GSK’s planned 2026 relaunch of BREXAFEMME for vulvovaginal candidiasis. SCYNEXIS is currently prioritizing its internal pipeline, specifically SCY-247, a second-generation triterpenoid that received FDA Fast Track and QIDP designations in January 2026. The company competes directly with Mycovia Pharmaceuticals, Cidara Therapeutics, and F2G Ltd, distinguishing itself as the pioneer of the first novel oral glucan synthase inhibitor class in over two decades. Leadership is spearheaded by President and CEO David Angulo, M.D., an infectious disease expert who ascended from the Chief Medical Officer role and previously held senior R&D positions at Brickell Biotech and Schering-Plough. The executive team includes CFO Ivor Macleod, whose 30-year pedigree includes serving as CFO of Eisai Inc. and North American CFO for Hoffmann-La Roche. The Board of Directors, chaired by Guy Macdonald (formerly of Tetraphase and Merck), features industry veterans such as Armando Anido and Philippe Tinmouth. Founded by a core group of former Aventis scientists, the company is backed by strategic partner GSK and institutional investors like Federated Hermes and BlackRock. This leadership team combines deep anti-infective drug development expertise with the commercial scale provided by their partnership with GSK.